Amylin’s Symlin Diabetes Therapy Gets FDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
The approval follows the company’s submission of a re-analysis of hypoglycemia data in response to an FDA “approvable” letter. The product is approved as an adjunct treatment for Type 1 and 2 diabetes.